Related Experiment Video
Updated: Jun 26, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Neutralizing epitopes of RSV and palivizumab resistance in Japan
Insights
Respiratory Syncytial Virus (RSV) causes severe infections in children. Continuous genetic analysis of the F protein is crucial due to emerging palivizumab-resistant mutations, aiding future vaccine development.
Area of Science:
- Virology
- Immunology
- Pediatrics
Background:
- Respiratory Syncytial Virus (RSV) is a primary cause of acute lower respiratory infections in young children.
- The RSV F protein is a key target for neutralizing antibodies due to its essential role and conserved nature.
Purpose of the Study:
- To highlight the importance of continuous genetic analysis of the palivizumab-binding region of the RSV F protein.
- To address the emergence of palivizumab-resistant mutations in RSV infections.
Main Methods:
- Review of existing literature on RSV antigenic targets and palivizumab resistance.
- Analysis of genetic data related to the F protein's palivizumab-binding site.
Main Results:
- Site II of the F protein is the target for palivizumab, a monoclonal antibody used for RSV prevention.
- Palivizumab-resistant mutations have been infrequently reported in children with RSV infections, particularly as palivizumab use expands.
Conclusions:
- Ongoing genetic surveillance of the F protein is necessary to monitor and combat palivizumab resistance.
- Advancements in RSV vaccine development are anticipated to significantly improve infection control in the coming decade.
Abstract:
Respiratory Syncytial Virus (RSV) is one of the most important viral pathogen related to acute lower respiratory infection in young children. The virus surface envelope contains the G, F, and SH proteins as spike proteins. The F protein is considered to be a major antigenic target for the neutralizing (NT) epitope as only the F protein is essential for cell infection among the three viral envelope proteins, and it is more highly conserved than the G protein. Recently, four antigenic targets related to NT activity have been reported;site I, site II, site IV, and site zero (0). Site II is the target for palivizumab used throughout the world to suppress severe RSV infection as passive immunity in high-risk children since 1998. Under the recent conditions in which indications for palivizumab administered subjects are being expanded, palivizumab-resistant mutations have been confirmed overseas in children with RSV infection, although they remain infrequent. Therefore, continuous genetic analysis of the palivizumab-binding region of the F protein is necessary. In addition, as vaccine development progresses, RSV infection control is expected to improve greatly over the next decade.
More Related Videos
Related Concept Videos
Cross-reactivity
Poliomyelitis
Respiratory Syncytial Virus Disease
Inhibitors Of Virion Release

